Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo combo shows promise for rare sarcoma

NCT ID NCT04605770

Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the combination of two chemotherapy drugs, pemetrexed and cisplatin, in 164 adults with advanced or recurrent soft tissue sarcoma. The goal is to see if this treatment can slow tumor growth in people who have already tried standard therapies. Participants will receive up to 6 cycles of the combination, followed by pemetrexed alone, and will be monitored for response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pemetrexed and cisplatin (chemotherapy drugs)
What this could lead to
If successful, this could provide a new chemotherapy option for people with advanced soft tissue sarcoma who have not responded to standard treatments.
What could go wrong
This is an early-phase trial with a small number of participants. The drugs may not work better than existing options, and side effects from chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 164 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2020

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * histologically confirmed, advanced/metastatic STS * Is ≥ 19 years of age * Eastern Cooperative Oncology Group performance status of 0 or 1 * measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 * laboratory values indicating adequate organ function * a documented postmenopausal woman, or is a premenopausal woman with negative urine or serum pregnancy test * life expectancy ≥ 12 weeks Exclusion Criteria: * previously received more than 2 regimens of cytotoxic chemotherapy * received chemotherapy, surgery to major organ, or radiotherapy within the last 2 weeks * ongoing toxicity (≥ CTCAE grade 2) from previous anticancer therapy * central nervous system (CNS) metastases requiring active treatment * diagnosis of second malignancy or has a history of active malignancy within the past 3 years * other medical conditions where the study treatment is intolerable * history of active infection * hypersensitivity to pemetrexed or any of its excipients * Co-administration with yellow fever vaccine * pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcoma,soft tissue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcoma,soft tissue

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Severance Hospital

    RECRUITING

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.